September 24, 2016 9:35 PM ET

Pharmaceuticals

Company Overview of Supernus Pharmaceuticals, Inc.

Company Overview

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products for the treatment of epilepsy include Oxtellar XR, an extended-release oxcarbazepine; and Trokendi XR, an extended-release topiramate. The company’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase IIb clinical trials for the treatment of ADHD. It is also ...

1550 East Gude Drive

Rockville, MD 20850

United States

Founded in 2005

344 Employees

Phone:

301-838-2500

Key Executives for Supernus Pharmaceuticals, Inc.

Founder, Chief Executive Officer, President, Secretary and Director
Age: 55
Total Annual Compensation: $523.4K
Chief Financial Officer and Vice President
Age: 65
Total Annual Compensation: $330.5K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 64
Total Annual Compensation: $356.4K
Chief Scientific Officer and Senior Vice President of Intellectual Property
Age: 59
Total Annual Compensation: $337.4K
Senior Vice President of Sales and Marketing
Age: 58
Total Annual Compensation: $291.6K
Compensation as of Fiscal Year 2015.

Supernus Pharmaceuticals, Inc. Key Developments

Supernus Pharmaceuticals Receives FDA Tentative Approval for Expanded Label of Trokendi XR to Include Migraine Prophylaxis in Adults

Supernus Pharmaceuticals announced that it has been granted tentative approval from the U.S. Food and Drug Administration for its Supplemental New Drug Application (sNDA) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults. The approval of the sNDA is tentative because the FDA has determined that the drug meets all of the required quality, safety, and efficacy standards for approval, but is subject to the pediatric exclusivity which expires March 28, 2017. Final approval may not be made effective until this exclusivity period has expired. In addition, the company said the FDA has granted final approval to expand the label for Trokendi XR for monotherapy treatment of partial onset seizures to include adults and pediatric patients 6 years and older, rather than 10 years and older.

Supernus Pharmaceuticals, Inc. Announces Management Changes

Supernus Pharmaceuticals, Inc. announced that Dr. M. James Barrett, Ph.D., has resigned from its Board of Directors effective August 10, 2016. With the announcement of Dr. Barrett's departure, the Board unanimously elected Charles W. Newhall, III, a current independent director, as Chairman. Mr. Newhall has served as a member of its Board since 2005, and currently serves as Chair of the Governance and Nominating Committee. He currently serves on the Boards of Interfusion, Neuropace, and Vitae Pharmaceuticals, and as Chairman Emeritus of the Industry Advisory Board for Greenspring Associates.

Supernus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended of June 30, 2016; Reiterates Earnings Guidance for the Full Year 2016

Supernus Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended of June 30, 2016. For the quarter, the company reported total revenue of $50,421,000 compared to $35,052,000 a year ago. Operating income was $10,440,000 compared to $3,076,000 a year ago. Earnings before income taxes were $10,732,000 compared to $2,667,000 a year ago. Net income was $10,018,000 compared to $2,005,000 a year ago. Diluted net income per share was $0.18 compared to $0.03 a year ago. For the six months, the company reported total revenue of $93,495,000 compared to $63,185,000 a year ago. Operating income was $15,757,000 compared to $6,507,000 a year ago. Earnings before income taxes were $15,917,000 compared to $3,647,000 a year ago. Net income was $15,005,000 compared to $2,923,000 a year ago. Diluted net income per share was $0.28 compared to $0.06 a year ago. For full year 2016, the company is reiterating guidance for net product sales and adjusting guidance for R&D expenses and operating income as set below: Net product sales will remain in the range of $200 million to $210 million. R&D expenses in the range of $50 million to $55 million, compared to the previously expected range of $55 million to $65 million. Operating income in the range of $32 million to $37 million, compared to the previously expected range of $28 million to $35 million.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Supernus Pharmaceuticals, Inc., please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.